

# 19th Annual Cardiovascular Update

FRIDAY, DECEMBER 4, 2020  
1 - 5 P.M. • LIVE VIA WEBINAR

## AGENDA

| <i><b>Time</b></i> | <i><b>Topic</b></i>   | <i><b>Presenter</b></i>                |
|--------------------|---|--|
| 1:00-1:05          | <b>Welcome</b>  | Matt Cavender, MD<br>Rick Stouffer, MD |
| 1:05-1:20          | What's New in the Primary Prevention Guidelines?  | Sid Smith, MD                          |
| 1:20-1:35          | Treating Hypertension in 2020   | Alan Hinderliter, MD                   |
| 1:35-1:50          | Expanding the role of cardiac rehabilitation  | Paula Miller, MD                       |
| 1:50-1:55          | <b>Questions</b>  |  |
| 1:55-2:00          | <b>BREAK</b>  |  |
| 2:00-2:15          | Cardiovascular Complications of COVID   | Joe Rossi, MD                          |
| 2:15-2:30          | COVID and athletes – What is the risk?  | Eugene Chung, MD                       |
| 2:30-2:45          | Impact of COVID on Cardiovascular Care Delivery in North Carolina                                 | Rick Stouffer, MD                      |
| 2:45-2:55          | <b>Questions</b>  |  |
| 3:55-3:00          | <b>BREAK</b>  |  |
| 3:00-3:05          | Case Presentation – Patient with Stable Angina  | Cassie Ramm, NP                        |
| 3:05-3:35          | The ISCHEMIA Trial – What were the results and how do they effect decisions on revascularization? | <u>Sripal</u> Bangalore, MD            |
| 3:35-3:45          | <b>Questions</b>  |  |
| 3:45-4:00          | Evaluation of Patients with Chest Pain in the Post-ISCHEMIA Trial Era                             | Joe Sivak, MD<br>Larry Klein, MD       |
| 4:00-4:15          | High Sensitivity Troponin – What are they and how do I use them?                                  | Charles Hicks, MD                      |
| 4:15-4:20          | <b>BREAK</b>  |  |
| 4:20-4:35          | Mitral Regurgitation in Patients with Heart Failure – What do I need to do?                       | John Vavalle, MD                       |
| 4:35-4:50          | Optimal use of SGLT2 inhibitors   | Jonathan Cicci, PharmD                 |
| 4:50-5:00          | <b>Questions</b>  |  |